SERVICES

Xtal has developed a suite of gene-to-structure discovery services that have a core of established and proven technologies whilst maintaining a rich resource of dynamic and active partnerships for cutting edge science and theory that can be quickly and seamlessly enabled for the richest tool set and result oriented research in our segment.

______________________________________________________________

XPRESS, XAMINE, and XPLORE form the core of our knowledge based services
and approaches. These three elements address cell and molecular biology, biochemistry, and biophysics respectively.

Our services were created as a technological 360 degree evaluation of your Candidate, to provide secondary and even tertiary validation of the MOA. We have devised programs and offerings that are specialized for start-ups, mid-sized, and large bio/pharma.

______________________________________________________________

Start-up offerings:

Our complete CRO Program is a unique approach that is geared specifically towards the pure start-up. We integrate into your discovery and candidate qualification stream to take your therapeutic from DNA to MOA understanding, to characterization and complete structure solution.

Many start-ups also experience difficulty in scaling their protocols to meet and blend with the technologies and techniques of large scale industrial grade production. Xtal science and scientist have repeatedly created protocols that work to industrial scale with excellent repeatability.

XTAL specializes in taking protocols from the research laboratory into the hands of seasoned industry technicians and experts to make the process viable and scalable in an industrial setting. The protocol is also optimized for reproducibility and cost effectiveness.

Our expertise and key industry affiliations will give you maximum benefits and quality data at a fraction of the cost and time it would take to internalize your requirements.

Retain maximum equity, qualify therapeutic actions prior to large scale funding and investment, ease cash requirements for initial start-up.

___________________________________________________________

Mid-sized offerings:            

Many of our mid-size customers are looking to improve the efficiency or increase the value of their present partnerships. We offer them the same services as we do for startups but with a much higher level of expertise and experience. Most of them have progressed their projects and are now looking to troubleshoot in-consistencies in the MOA.  We have the ability and the capability to step into a project and carry on without missing a beat. Our unique knowledge based approach lets us get up to speed in an instant.

Back-up research projects are essential for many companies to augment their pipeline. We offer them a lot of expertise in carrying out secondary projects.

Generic CRO’s are geared to do one thing very well, but when research does not go as planned then they are  at a loss as to how to proceed. Xtal helps in such scenarios using our 360 degree approach to fish out the problem and propose alternative pathways

Our Xamine program offers a wide variety of choices in developing a secondary assay to complement or supplement the data gathered from the primary assays.

__________________________________________________________

Large sized offerings:

Many, or all, of our large pharma customers have in house resources that have been built over time. We supplement their throughput by helping in the process and removing bottlenecks. Like many other pharmaceutical companies looking to get ahead the large companies also have a full pipeline that gets thinned as research proceeds along. In such a scenario there has to be back up projects and all have to progress at a fast pace. Xtal is very proficient in carrying out routine tasks and takes pride in serving the R&D divisions in their research efforts. We can provide good amounts of source materials for their crystallographic or assay methods. We understand that being a link in the drug discovery chain is very important for the success of the whole program and we are committed to ensuring only the highest level of competency and partnering experience.

Xtal also has the capacity to synergize your in-house candidate analysis process and create a “final step” layer that can better analyze your candidates that have already cleared some critical hurdles through your own internal analysis. This hybrid approach and hand-off can serve to optimize your drug discovery pipeline in ways not possible before. Through our 360 degree approach and superior resource pool, we can provide a better answer to your question, “will this candidate succeed?” Through our analysis, smarter and faster decisions can be the result. This outsourced strategy can give you significant savings with your pipe line development.

Whether its 500mg of protein for high throughput assay or protocol development, Xtal's service packages can be highly customized to meet your needs.